drug_type
RELEVANT_DRUG
intervention_type
Genetically modified cellular immunotherapy (CAR-T)
drug_description
Autologous dual-target BCMA/CD19 chimeric antigen receptor T-cell (CAR-T) therapy produced via lentiviral transduction; single IV infusion to deplete CD19+ B cells and BCMA+ plasma cells in autoimmune kidney disease.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express dual chimeric antigen receptors targeting CD19 and BCMA. On engagement with these antigens on B cells and plasma cells, the CAR-T cells become activated and kill targets via perforin/granzyme and death receptor pathways, depleting CD19+ B cells and BCMA+ plasmablasts/plasma cells to reduce pathogenic autoantibody production in autoimmune kidney disease.
drug_name
FKC288
nct_id_drug_ref
NCT06285279